BUZZ.CN - Pharmadrug Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.0150
0.0000 (0.00%)
At close: 11:37AM EDT
Stock chart is not supported by your current browser
Previous Close0.0150
Open0.0150
Bid0.0150 x 0
Ask0.0200 x 0
Day's Range0.0150 - 0.0150
52 Week Range0.0150 - 0.2600
Volume27,500
Avg. Volume82,596
Market Cap1.25M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings DateMay 26, 2020 - May 31, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Pharmadrug Inc. Enters Secured Loan Agreement and LOI for Possible Business Combination
    Newsfile

    Pharmadrug Inc. Enters Secured Loan Agreement and LOI for Possible Business Combination

    Toronto, Ontario--(Newsfile Corp. - February 7, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company") is pleased to announce that it has secured a private loan (the "Loan") of $250,000 from an arm's length third party lender (the "Lender"). The Loan carries an interest rate of 9% per annum accruing every 90 days, payable on maturity with such interest increasing to 15% per annum from the date of the occurrence of an event ...

  • Newsfile

    Pharmadrug Announces Q3 2019 Financial Results

    Toronto, Ontario--(Newsfile Corp. - November 29, 2019) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company" or "Pharmadrug"), a leading European medical cannabis distribution company, today announced its financial results for the third quarter ending September 30, 2019. The Company's full Management's Discussion and Analysis ("MD&A") is available on SEDAR (www.sedar.com)."Q3 was Pharmadrug's first full quarter of operations in Germany since acquiring Pharmadrug Production GmbH in May 2019. Since then, we have taken significant measures to ...

  • Israeli Government in Discussions on Medical Cannabis Export Framework & Appointment of New Board Member
    Newsfile

    Israeli Government in Discussions on Medical Cannabis Export Framework & Appointment of New Board Member

    Toronto, Ontario--(Newsfile Corp. - November 19, 2019) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company" or "Pharmadrug") would like to update investors on developments from Israel's Ministry of Health regarding the export law on medical cannabis passed in January of 2019 (the "Export Law"). It was revealed late last week that the Israeli Ministry of Health (the "Ministry") will soon be publishing its cannabis export guidelines, which will enable the commencement of ...

  • Newsfile

    Pharmadrug Signs Major Canadian Supply Agreement with Canada House Wellness for German Distribution as German Governing Party Moves Closer to Recreational Cannabis Legislation

    Toronto, Ontario--(Newsfile Corp. - October 31, 2019) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company" or "Pharmadrug") is pleased to announce a multi-year supply agreement (the "Supply Agreement") between 80% owned subsidiary Pharmadrug Production GmbH and Canada House Wellness Group Inc. (CSE: CHV) (the "Grower" or "Canada House").Under the Supply Agreement, all medical cannabis will be sold through Pharmadrug's own 'Cannabion' brand. Terms for the first year are 250 kg of dry ...

  • Aura Health Announces Name Change to Pharmadrug to Reflect Focus on Pharmaceutical Medicine
    Newsfile

    Aura Health Announces Name Change to Pharmadrug to Reflect Focus on Pharmaceutical Medicine

    Toronto, Ontario--(Newsfile Corp. - October 21, 2019) - Aura Health Inc. ("Aura") (CSE:BUZZ) (OTC: LMLLF) is pleased to announce that it has completed its name change from Aura Health Inc. to Pharmadrug Inc. ("Pharmadrug" or the "Company") (the "Name Change"). Aura's shareholders approved the name change at the annual and special meeting of shareholders held on October 3, 2019.The CUSIP number assigned to the Company's shares following the name change is: CUSIP 71716W105 ...

  • Aura Announces Extension of Maturity and Partial Repayment of Bridge Loan Facility
    Newsfile

    Aura Announces Extension of Maturity and Partial Repayment of Bridge Loan Facility

    Toronto, Ontario--(Newsfile Corp. - October 3, 2019) - Aura Health Inc. (CSE: BUZZ) (OTC: LMLLF) (the "Company" or "Aura") is pleased to announce that the CAD$3 million bridge loan facility (the "Bridge Loan Facility") entered into by the Company and a private lender (the "Lender") on May 8, 2019, has been amended to mature in six months on March 24, 2020 (the "Maturity Date"). The outstanding principal and accrued interest on the Bridge ...

  • Aura's Pharmadrug Signs Major Supply Agreement Setting Stage for Brand Launch & Expanded Distribution
    Newsfile

    Aura's Pharmadrug Signs Major Supply Agreement Setting Stage for Brand Launch & Expanded Distribution

    Toronto, Ontario--(Newsfile Corp. - September 19, 2019) - Aura Health Inc. (CSE:BUZZ) (OTC:LMLLF) (the "Company" or "Aura") is pleased to announce a multi-year supply agreement (the "Supply Agreement") between 80% owned subsidiary Pharmadrug Production GmbH ("Pharmadrug") and Israel-based My Green Fields Ltd. ("My Green Fields" or the "Grower").Beginning the five-year supply agreement, the medical cannabis product will consist initially of dry flower and complemented soon after by oils and extracts, all sold under Pharmadrug's ...

  • Aura Announces Pharmadrug Operational & Investor Relations Update
    GlobeNewswire

    Aura Announces Pharmadrug Operational & Investor Relations Update

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ, OTCQB:LMLLF) is pleased to provide an operational update on Pharmadrug Production GmbH (the “German Business” or “Pharmadrug”) and additional resources allocated to investor relations. Following Aura’s German operational update on June 5, 2019, Pharmadrug received its second, much larger shipment of medical cannabis from Netherlands at the end of June.

  • Aura Signs Master Grower for Israel
    GlobeNewswire

    Aura Signs Master Grower for Israel

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce the signing of master grower, Adrian Richelmi, to build and operate HolyCanna’s 60,000 square foot greenhouse facilty in Israel. Adrian offers over 15 years of expertise in growing medical cannabis for both soilless soil and hydroponics projects.  His resume includes designing and building large scale production facilities along with extensive knowledge of industry standards and best construction practices. Daniel Cohen, CEO of Aura, added, “We welcome Adrian to our team to help with the next stage of building Aura’s vertical integration between Israel and Germany.

  • Aura Provides Clarification on Pharmadrug’s Supply Agreements and Relationship With Bedrocan
    GlobeNewswire

    Aura Provides Clarification on Pharmadrug’s Supply Agreements and Relationship With Bedrocan

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) wishes to clarify the nature of the supply arrangement by which Pharmadrug Production GmbH (“Pharmadrug”) is importing and distributing cannabis to pharmacies in Germany. In a press release dated June 5th, 2019, the Company announced that Pharmadrug has ordered its second cannabis shipment from Bedrocan International B.V. (“Bedrocan”) and in a press release dated May 17th, 2019, the Company announced that Pharmadrug has supply agreements in place with Bedrocan.

  • Aura Announces Appointment of Al Quong to Its Board of Directors
    GlobeNewswire

    Aura Announces Appointment of Al Quong to Its Board of Directors

    Aura Health Inc. (the "Company" or “Aura”) (CSE:BUZZ) is pleased to announce the appointment of Al Quong to its board of directors, subject to regulatory approval. Mr. Quong is an experienced finance professional, with more than 25 years of operational and advisory experience in various capacities and industries. Al is currently Chief Financial Officer for the Fovere Group of Companies, a boutique private equity firm which specializes in investments and financing within the real estate, natural & organic food and renewable energy sectors.  He previously served as Chief Financial Officer for Nutritional High International Inc. (EAT.CN) and The Tinley Beverage Company Inc. (TNY.CN), and Assurance Senior Manager at KPMG Calgary.

  • Aura Initiates Investor Relations Strategy
    GlobeNewswire

    Aura Initiates Investor Relations Strategy

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that it has engaged two firms to assist with an investor relations strategy for the Company. Adelaide Capital Markets (“Adelaide”) and CanaCom Group, the parent company of The Deep Dive (“Deep Dive”) will work closely with Aura’s management team to develop and implement a comprehensive marketing campaign.

  • Aura Announces Strategic Entry Into the European Market With the Closing of the Acquisition of Pharmadrug
    GlobeNewswire

    Aura Announces Strategic Entry Into the European Market With the Closing of the Acquisition of Pharmadrug

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that it has closed the previously announced (May 8, 2019) acquisition of an 80% equity interest in Pharmadrug Production GmbH (“Pharmadrug”) for total consideration of €5.0 million. Pharmadrug is a cash flow positive German pharmaceutical distribution company with over 20 years of operating history and a Schedule I European Union narcotics license allowing for the distribution of medical cannabis to pharmacies in Germany and throughout the Eurozone as markets become legalized. Pharmadrug has supply agreements in place with Bedrocan International B.V., Canadian Licensed Producers, and is currently supplying medical cannabis to pharmacies in Germany.

  • Aura Announces Supply Agreement With FSD Pharma & Conditions Met to Close German Acquisition
    GlobeNewswire

    Aura Announces Supply Agreement With FSD Pharma & Conditions Met to Close German Acquisition

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce a multi-year supply agreement with FSD Pharma Inc. (“FSD”) and that milestones have been met to allow the Company to close the acquisition of an 80% equity interest in Pharmadrug Production GmbH (“Pharmadrug”), as previously announced on January 25, 2019 and April 17, 2019. Pharmadrug is a cash flow positive German pharmaceutical distribution company with over 20 years of operating history and a Schedule I European Union narcotics license that allows it to distribute medical cannabis to pharmacies in Germany and throughout the Eurozone as markets become legalized.

  • Aura Signs Definitive Agreement Disposing of U.S. Cannabis Certification Clinics
    GlobeNewswire

    Aura Signs Definitive Agreement Disposing of U.S. Cannabis Certification Clinics

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that its wholly owned subsidiary, Green Global Properties Inc. (“GGPI”), has entered into a definitive purchase and sale agreement dated April 30, 2019 (the “PSA”) with Empower Healthcare Assets Inc. (“Empower”), a Delaware corporation and wholly-owned subsidiary of Empower Clinics Inc (CBDT.CN), pursuant to which Empower has acquired Aura’s indirectly-held U.S. cannabis assets (the “U.S. Assets”), as previously announced on April 17, 2019 (the “Transaction”). The U.S. Assets being sold consist of three medical cannabis clinics in the U.S. sun belt, in respect of which GGPI owned a 30% interest through three limited liability companies.

  • Aura Health Announces $5.82 Million Closing of the Second Tranche of Its Subscription Receipt Offering and Share Exchange Transaction
    GlobeNewswire

    Aura Health Announces $5.82 Million Closing of the Second Tranche of Its Subscription Receipt Offering and Share Exchange Transaction

    NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE.

  • Aura Announces Appointment of Alain Dobkin to its Board of Directors
    GlobeNewswire

    Aura Announces Appointment of Alain Dobkin to its Board of Directors

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce the appointment of Alain Dobkin to its board of directors, subject to regulatory approval. Alain is a private equity investor with more than 20 years of investment and advisory experience, including 13 years with Citigroup Investment Bank in New York and Tel Aviv. Additionally, he was the Director of Citigroup’s Israel Investment Bank, where he served as advisor on strategic mergers and acquisitions and equity and debt capital raising transactions from both public and private markets globally.

  • Aura Announces Signing of Definitive Share Purchase Agreement to Acquire Licenced Medical Cannabis Distributor in Germany
    GlobeNewswire

    Aura Announces Signing of Definitive Share Purchase Agreement to Acquire Licenced Medical Cannabis Distributor in Germany

    NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE.

  • Aura Health Announces Closing of $1.9 Million on the First Tranche of Subscription Receipt Financing
    GlobeNewswire

    Aura Health Announces Closing of $1.9 Million on the First Tranche of Subscription Receipt Financing

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that it has closed the first tranche (the “First Tranche Closing”) of its previously announced “best efforts” private placement subscription receipt offering (the “Offering”) led by Mackie Research Capital Corporation (the “Lead Agent”), the lead agent and sole book runner, with a syndicate consisting of Haywood Securities Inc., PI Financial Corp., and Foundation Markets Inc. (together with the Lead Agent, the “Agents”). The Offering is being conducted on an agency basis for the issuance of up to 33,000,000 subscription receipts of Aura (each, a “Subscription Receipt” and collectively, the “Subscription Receipts”) at a price of $0.22 per Subscription Receipt (the “Issue Price”) for gross proceeds of up to $7,260,000 (subject to the Agent’s Option described below).

  • Aura Health Provides Further Clarity Regarding Offering and Strategic Investor
    GlobeNewswire

    Aura Health Provides Further Clarity Regarding Offering and Strategic Investor

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to provide further clarity on the press release dated February 21, 2019 with regards to the upsized private placement subscription receipt offering (the “Offering”), including the participation by a strategic investor and the divestiture by Aura of certain non-material U.S. assets. Aura is currently in the process of divesting its 30% interest in four medical marijuana clinics in the U.S. (the “U.S. Assets”). The proceeds from the sale of the U.S. Assets are not expected to be material to the Company.

  • With a Strategic Investment by Aleafia Health, Aura Health Announces Increase to Previously Announced Brokered Subscription Receipt Financing to $7.26 Million
    GlobeNewswire

    With a Strategic Investment by Aleafia Health, Aura Health Announces Increase to Previously Announced Brokered Subscription Receipt Financing to $7.26 Million

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that, due to investor demand, the Company has increased the size of its previously announced private placement subscription receipt offering (the “Offering”) to a maximum of $7,260,000 and will be conducted on an agency basis for the issuance of up to 33,000,000 subscription receipts of Aura (each, a “Subscription Receipt” and collectively, the “Subscription Receipts”) at a price of $0.22 per Subscription Receipt (the “Issue Price”). The Offering is being led by Mackie Research Capital Corporation (the “Lead Agent”), as lead agent and sole book runner, along with Haywood Securities Inc., PI Financial Corp., and Foundation Markets Inc. (together with the Lead Agent, the “Agents”).

  • Aura Health Announces Pricing of Previously Announced $5.0 Million Brokered Subscription Receipt Financing
    GlobeNewswire

    Aura Health Announces Pricing of Previously Announced $5.0 Million Brokered Subscription Receipt Financing

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce the price and terms of its brokered private placement subscription receipt offering previously announced on February 4, 2019 (the “Offering”), led by Mackie Research Capital Corporation (the “Lead Agent”), the lead agent and sole book runner, with Haywood Securities Inc., PI Financial Corp., and Foundation Markets Inc. (together with the Lead Agent, the “Agents”). The Offering will be conducted on an agency basis for the issuance of up to 22,727,272 subscription receipts of Aura (each, a “Subscription Receipt” and collectively, the “Subscription Receipts”) at a price of $0.22 per Subscription Receipt (the “Issue Price”) for gross proceeds of up to $5,000,000 (subject to the Agent’s Option described below).

  • Aura Health Announces $5 Million Brokered Subscription Receipt Financing
    GlobeNewswire

    Aura Health Announces $5 Million Brokered Subscription Receipt Financing

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that it has engaged Mackie Research Capital Corporation (the “Lead Agent”) to act as lead agent and sole book runner, along with Haywood Securities Inc., PI Financial Corp., and Foundation Markets Inc. (together with the Lead Agent, the “Agents”) to sell, by way of private placement, on a “best efforts” basis (the “Offering”) up to $5,000,000 of subscription receipts of Aura (each, a “Subscription Receipt” and collectively, the “Subscription Receipts”) at a price per Subscription Receipt, which will be determined in the context of the market (the “Issue Price”). The Offering is being completed in connection with the proposed acquisition of an 80% equity interest in Pharmadrug Production GmbH (the “Acquisition”), previously announced in a press release dated January 25, 2019.

  • Israel Passes Cannabis Export Law, Paving Path for Aura’s European Distribution
    GlobeNewswire

    Israel Passes Cannabis Export Law, Paving Path for Aura’s European Distribution

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased with the final approval of Israel’s export law for medical cannabis. On Sunday, January 27, the Israeli government announced the new law, approving the export of Israeli-grown cannabis to the global market. The law makes Israel the third country in the world, after Canada and the Netherlands, to approve export of medicinal cannabis.

  • Aura Announces Binding LOI to Acquire Licenced Medical Cannabis Distributor in Germany
    GlobeNewswire

    Aura Announces Binding LOI to Acquire Licenced Medical Cannabis Distributor in Germany

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that the Company has entered into a binding letter of intent (the “LOI”) to acquire 80% of Pharmadrug Production GmbH (“Pharmadrug”) for EUR5,000,000. Pharmadrug is a cash flow positive German pharmaceutical distribution company with over 20 years of operating history. Pharmadrug has a Schedule I European Union narcotics licence that allows the business to distribute medical cannabis to pharmacies in Germany and the rest of the Eurozone as markets become legalized.